Sourasky Medical Center (Ichilov)
| Израиль | Түркия | Австрия | |
| Галлий 68 (ПСМА) көмегімен ПЭТ-КТ | бастап $1,950 | бастап $650 | бастап $2,450 |
Сіз Bookimed қызметтері үшін төлемейсіз. Сайттағы галлий 68 (псма) көмегімен пэт-кт-ті бағалары клиниканың баға тізіміне сәйкес келеді. Сіз жеткенде тікелей клиникада төлейсіз. Бөліктермен төлеу қолжетімді.
Bookimed Сіздің қауіпсіздігіңізді қамтамасыз етеді. Біз тек галлий 68 (псма) көмегімен пэт-кт-тің жүргізу үшін жоғары халықаралық стандарттарға сәйкес келетін клиникалармен ғана жұмыс істейміз. Олардың бүкіл әлем бойынша халықаралық науқастарға қызмет көрсету үшін қажетті лицензиялары бар.
Bookimed тегін көмек және қолдау ұсынады. Жеке медициналық координатор сапарға дейін, кезінде және кейін Сізбен байланыста. Галлий 68 (ПСМА) көмегімен ПЭТ-КТ процедурасы кезінде Сіз басқа елде жалғыз қалмайсыз.
Клиника Ассута (Assuta) — Израильдегі ең ірі жеке медициналық орталық. Госпиталь онкология, ортопедия, нейро-, кардиохирургия және бедеулікті емдеуге маманданған. Елдегі барлық операциялардың 13% Ассутада өткізіледі, бұл оны хирургия бойынша жетекші орталық етеді.
Емдеудің сапасы мен қауіпсіздігі үшін аурухана американдық Joint Commission International аккредитациясын алды.
Әр жыл сайын Ассута желісінің дәрігерлері 92 000-нан астам операция, 685 000 диагностикалық процедура және 16 000 ЭКО циклдарын өткізеді.
Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.
He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.
He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.
His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.
Dr. Barak Rosenzweig, MD, directs the Urological Oncology Service at Sheba Medical Center. He is a uro-oncologic surgeon with nearly 20 years of experience. He treats complex urologic cancers with advanced robotic and minimally invasive methods. He is listed among Israel’s Best Doctors by Forbes.
Expertise includes tumors of the prostate, kidney, bladder, testis, and upper urinary tract. He performs robotic radical prostatectomy, kidney-sparing partial nephrectomy, and advanced laparoscopy. Diagnostics include MRI-guided fusion biopsy and imaging-based personalized planning.
He completed a Urological Oncology fellowship at Memorial Sloan Kettering Cancer Center. He is a Senior Physician in the Department of Urology and a Clinical Senior Lecturer at Tel Aviv University. He is a graduate of the Sheba Talpiot program. He is an active researcher with over 200 publications in urologic oncology.
Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.
He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.
He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.
Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.
He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.
Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.